Biggest News Aggregation in the World
📰 Gynecologic Program News

Gynecologic Program News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Gynecologic Program. Real-time updates on events, politics, business and more.

Keytruda Plus Chemo Improves Progression-Free Survival in Cervical Cancer

The addition of Keytruda to external beam radiotherapy and concurrent chemotherapy, followed by brachytherapy, resulted in statistically significant and clinically meaningful improvements in progression-free survival in patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer.
United States Domenica Lorusso Us Oncology Research Network Drug Administration Catholic University Of Rome University Of Arizona College Medicine

Keytruda Plus Chemoradiotherapy Bests Standard of Care in Advanced Cervical Cancer

Adding Keytruda to EBRT and chemotherapy, followed by brachytherapy, improved progression-free survival in patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer.
Domenica Lorusso Us Oncology Research Network International Federation Of Gynecology Division Of Gynecologic Oncology Gynecologic Program University Of Arizona College Medicine

Pembrolizumab Plus Chemoradiotherapy Shows Statistically Significant PFS Benefit vs SOC in High-Risk Locally Advanced Cervical Cancer

The addition of pembrolizumab to external beam radiotherapy and concurrent chemotherapy, followed by brachytherapy, resulted in statistically significant and clinically meaningful improvements in progression-free survival when compared with placebo plus EBRT/chemoradiotherapy/brachytherapy in patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer.
United States Domenica Lorusso International Federation Of Gynecology Gynecologic Program Catholic University Of Rome University Of Arizona College Medicine

Avutometinib/Defactinib Combo Generates Early Efficacy Signals in Low-Grade Serous Ovarian Cancer

Bradley J. Monk, MD, FACS, FACOG, discusses the rationale for investigating avutometinib plus defactinib in patients with low-grade serous ovarian cancer, key findings from RAMP 201, and how this research may influence the ovarian cancer treatment paradigm going forward
University Of Arizona United States City Of United Kingdom Susana Banerjee Creighton University School Of Medicine At St

Dr Monk on Avutometinib Plus Defactinib in Low-Grade Serous Ovarian Cancer

Bradley Monk, MD, FACS, FACOG, discusses findings from the phase 2 RAMP 201 trial in patients with low-grade serous ovarian cancer and the importance of these results within the context of the larger ovarian cancer treatment paradigm. 
United States University Of Arizona Division Of Gynecologic Oncology University Of Arizona College Medicine Us Oncology Research Network Arizona Oncology Us Network

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science